Left ventricular assist device: Difference between revisions
Jump to navigation
Jump to search
imported>Meg Taylor No edit summary |
mNo edit summary |
||
Line 3: | Line 3: | ||
#[[Thoratec]] - Heartmate2 market capital $2B US | #[[Thoratec]] - Heartmate2 market capital $2B US | ||
#[[Ventracor]] - VentrAssist | #[[Ventracor]] - VentrAssist | ||
#[[Heartware]] | #[[Heartware]][[Category:Suggestion Bot Tag]] |
Latest revision as of 06:00, 11 September 2024

A left ventricular assist device or LVAD is a pump which runs in parallel with a heart to boost the blood flow. The main reason for a patient to have a LVAD implanted is for bridge to transplant (BTT) or destination therapy (DT). Currently, the top three companies in this field are: